Fig. 1From: Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factorsSurvival data of first-line targeted therapy for advanced renal carcinomaBack to article page